Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
IRIX 
IRIDEX Corporation (IRIX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: IRIX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -41.01% | Avg. Invested days 24 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 14.77M USD | Price to earnings Ratio - | 1Y Target Price 2 |
Price to earnings Ratio - | 1Y Target Price 2 | ||
Volume (30-day avg) - | Beta 0.61 | 52 Weeks Range 0.78 - 2.41 | Updated Date 06/29/2025 |
52 Weeks Range 0.78 - 2.41 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.43 |
Earnings Date
Report Date 2025-06-18 | When After Market | Estimate -0.12 | Actual -0.1008 |
Profitability
Profit Margin -14.61% | Operating Margin (TTM) -1.72% |
Management Effectiveness
Return on Assets (TTM) -9.54% | Return on Equity (TTM) -106.93% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 12829343 | Price to Sales(TTM) 0.3 |
Enterprise Value 12829343 | Price to Sales(TTM) 0.3 | ||
Enterprise Value to Revenue 0.26 | Enterprise Value to EBITDA -3.61 | Shares Outstanding 16789000 | Shares Floating 11118197 |
Shares Outstanding 16789000 | Shares Floating 11118197 | ||
Percent Insiders 27.93 | Percent Institutions 18.76 |
Upturn AI SWOT
IRIDEX Corporation
Company Overview
History and Background
IRIDEX Corporation, founded in 1989, develops, manufactures, and markets innovative laser-based medical devices for the treatment of glaucoma and other ophthalmic diseases. They focus on developing minimally invasive procedures.
Core Business Areas
- Ophthalmology: Develops and markets laser systems and delivery devices for treating glaucoma, diabetic macular edema (DME), and other retinal diseases.
Leadership and Structure
Dominique Beckers serves as the CEO. The company has a typical corporate structure with departments for R&D, manufacturing, sales, marketing, and finance.
Top Products and Market Share
Key Offerings
- CYCLO G6 Laser System: Used for MicroPulse Transscleral Cyclophotocoagulation (MP-TSCPC) to treat glaucoma. IRIDEX is a major player in this glaucoma treatment market. Competitors include Lumenis and Ellex (acquired by Nova Eye Medical). Revenue breakdown is unavailable. However, this is their leading product line.
- MicroPulse PASCAL Laser System: Used for treating retinal diseases like diabetic retinopathy and macular edema with MicroPulse technology. Competitors include Topcon, Quantel Medical.
Market Dynamics
Industry Overview
The ophthalmic laser market is driven by the aging population, increasing prevalence of diabetes (leading to diabetic retinopathy), and advancements in laser technology for minimally invasive procedures.
Positioning
IRIDEX is positioned as a leader in laser-based solutions for glaucoma and retinal diseases, particularly in MicroPulse technology. They have a competitive advantage in MP-TSCPC for glaucoma.
Total Addressable Market (TAM)
The total addressable market for glaucoma and retinal disease treatment devices is estimated at several billion dollars annually. IRIDEX is positioned to capture a share of this market through its innovative laser systems. Specific TAM value is not available.
Upturn SWOT Analysis
Strengths
- Innovative MicroPulse technology
- Established brand name in ophthalmology
- Strong presence in glaucoma treatment market
- Growing installed base of laser systems
Weaknesses
- Limited product portfolio compared to larger competitors
- Dependence on ophthalmology market
- Variable quarterly financial results
- Relatively small market capitalization
Opportunities
- Expanding applications of MicroPulse technology
- Growing adoption of minimally invasive glaucoma surgery (MIGS)
- Geographic expansion into emerging markets
- Strategic partnerships with ophthalmic clinics and hospitals
Threats
- Competition from larger medical device companies
- Technological advancements by competitors
- Reimbursement pressures from healthcare providers
- Economic downturns impacting capital equipment spending
Competitors and Market Share
Key Competitors
- LMNR
- NVA.AX
- ALGN
Competitive Landscape
IRIDEX's advantage lies in its MicroPulse technology and established brand. Its disadvantage is its smaller size compared to competitors.
Growth Trajectory and Initiatives
Historical Growth: IRIDEX's growth has been driven by adoption of its MicroPulse technology. Data can be found on financial news sources and is subject to change
Future Projections: Analyst projections vary. Data can be found on financial news sources and is subject to change
Recent Initiatives: Recent initiatives include expanding sales and marketing efforts, developing new laser systems, and pursuing strategic partnerships.
Summary
IRIDEX is a key player in ophthalmology lasers with strengths in MicroPulse technology, especially for glaucoma treatment. While their smaller size compared to rivals is a constraint, expanding applications of MicroPulse and emerging markets present growth opportunities. The company must continue innovating to face competition and reimbursement challenges, especially with the increased number of competitors in the space.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company press releases
- Company investor relations
- Third-party market research reports
- Financial news sources
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market data and financial information are subject to change. Past performance is not indicative of future results. Conduct thorough research before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About IRIDEX Corporation
Exchange NASDAQ | Headquaters Mountain View, CA, United States | ||
IPO Launch date 1996-02-15 | CEO, President & Director Mr. Patrick Mercer | ||
Sector Healthcare | Industry Medical Devices | Full time employees 93 | Website https://www.iridex.com |
Full time employees 93 | Website https://www.iridex.com | ||
IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments. The company also provides delivery devices, including slit lamp adapter, which allows the physician to utilize a standard slit lamp in diagnosis and treatment procedures; TxCell scanning laser delivery system that allows the physician to perform multi-spot pattern scanning; and laser indirect ophthalmoscope for use in procedures to treat peripheral retinal disorders. In addition, it offers MicroPulse P3 Probe, which is used with its Cylco G6 laser system to perform transscleral laser therapy; G-Probe and G-Probe Illuminate, which are used in procedures to treat refractory glaucoma; and EndoProbe family of products that are used for endophotocoagulation. The company serves ophthalmologists, research and teaching hospitals, government installations, surgical centers, hospitals, veterinary practices, and office clinics through direct and independent sales force in the United States, as well as through independent distributors internationally. It operates in the United States, Europe, the Middle East, Africa, the Asia/Pacific region, and the Americas. The company was formerly known as IRIS Medical Instruments, Inc. and changed its name to IRIDEX Corporation in November 1995. IRIDEX Corporation was incorporated in 1989 and is headquartered in Mountain View, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.